| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3848399 | American Journal of Kidney Diseases | 2013 | 12 Pages |
Abstract
Rasburicase is effective in reducing serum uric acid levels in adults with TLS but at a significant cost, and evidence currently is lacking in adults to report whether rasburicase use improves clinical outcomes compared with other alternatives. Until new evidence is available, use of rasburicase may be limited to adult patients with a high risk of TLS.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Maria A. MD, PhD, Gregory DDS, MLS, Shana L. MS, Abdulla MD, MBA, FRCP,